ADXN.SW

Addex Therapeutics Ltd [ADXN.SW] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

ADXN.SW Stock Summary

In the News

ADXN.SW Financial details

Company Rating
-
Market Cap
15.38M
Income
-11.55M
Revenue
2.05M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
24
Optionable
No
Shortable
Yes
Earnings
05 May 2021
P/E
-0.42
Forward P/E
-
PEG
0.07
P/S
2.49
P/B
1.23
P/C
-
P/FCF
-0.49
Quick Ratio
2.66
Current Ratio
2.97
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.2
EPS next Y
-
EPS next Q
-
EPS this Y
4.44%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
46.1%
Revenue last 5Y
-25.12%
Revenue Q/Q
-48.05%
EPS Q/Q
-8.63%
-
-
-
-
SMA20
-
SMA50
-16.67%
SMA100
-16.67%
Inst Own
-
Inst Trans
-
ROA
-188%
ROE
-242%
ROC
-2.64%
Gross Margin
100%
Oper. Margin
-541%
Profit Margin
-563%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.0362-0.26
52W High
-
52W Low
-
RSI
59.56
Rel Volume
0.24
Avg Volume
977.19K
Volume
232.08K
Perf Week
19.6%
Perf Month
7.94%
Perf Quarter
-28.13%
Perf Half Y
-23.92%
-
-
-
-
Beta
1.747
-
-
Volatility
0%, 0%
Prev Close
3.82%
Price
0.0598
Change
3.1%

Something similar

Top by Market Cap
VFINX
V
ABEA.DE
LLY.SW
JPM
Same Sector
0HCK.L
AKBA
HQDA
SNYR
0503.HK
Same Price Range
NBVA.V
SANT
0159.HK
0690.HK
1901.HK
Similar Market Cap
ROAM
NYMX
ANGS.L
SNWV
DFDU.L

Company Profile

Healthcare Biotechnology
  • Volume Average 977.19K
  • Market Capitalization 15.38M
  • Employee 24
  • CEO Mr. Timothy Mark Dyer
  • Headquarters Geneva,CH
  • IPO Date 2007-05-22
  • Website https://www.addextherapeutics.com

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot–Marie–Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.